Hers, Hims and Ozempic
Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...
Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth ...
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
Shares of Hims & Hers Health (HIMS) sank in after-hours trading after the healthcare company reported earnings for its fourth ...
Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's ...
Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...
Hims & Hers faces new headwinds in its weight management segment with the Food and Drug Administration ending the shortage of ...
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results